TransMedics Group, Inc.

Electromedical & Electrotherapeutic Apparatus

TMDX Medical Devices & Diagnostics People in Medical Devices & Diagnostics SEC CIK 0001756262 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$2.84B
34,675,145 shares Covers every share class this company has on file.
Insiders on file
12
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$112.91M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
3.98%
insider-held value divided by market capitalisation

What TransMedics Group, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$605.49M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
$190.30M
FY2025 profit for the period, from this company’s own annual XBRL filings to the SEC
Employees
898
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at TransMedics Group, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against TransMedics Group, Inc..
Insider Reported role Shares Value Last action
Officers 6
Tamer I Khayal Other Executive 36,042 $3.24M S Open-market sale Mar 3, 2025 position reported
Nicholas Corcoran Executive 29,831 $2.68M A Grant or award Jul 10, 2026 position reported
Stephen Gordon CFO 21,299 $1.92M M Option exercise or conversion Jun 3, 2024 position reported
Giovanni Cecere Other Executive 19,057 $1.71M A Grant or award Feb 18, 2026 position reported
Gerardo Hernandez CFO 14,689 $1.32M A Grant or award Jul 10, 2026 position reported
Anil P Ranganath Anil P Ranganath Executive 13,091 $1.18M S Open-market sale Mar 2, 2026 position reported
Officers who also sit on the board 1
Waleed H Hassanein CEO 616,433 $55.47M A Grant or award Jul 10, 2026 position reported
Directors 5
Edwin M. Kania Jr. Board Member 306,952 $27.62M A Grant or award May 20, 2026 position reported
James R. Tobin Board Member 177,205 $15.94M G Bona fide gift Aug 17, 2026 position reported
David Weill Board Member 12,134 $1.09M A Grant or award May 20, 2026 position reported
Merilee Raines Board Member 4,059 $365.2K A Grant or award May 20, 2026 position reported
Thomas James Gunderson Board Member 4,059 $365.2K S Open-market sale Jun 15, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

TransMedics Group, Inc. (TMDX) filed a Form 8-K under Item 5.02 (directors and officers) on Sep 10, 2026

Director or officer change filing

The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.

Form 8-K filed Sep 10, 2026, items 5.02, 7.01, 9.01. SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Waleed H Hassanein sold 25,000 TransMedics Group, Inc. (TMDX) shares for $4,375,000 on Aug 22, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Waleed H Hassanein sold 25,000 TransMedics Group, Inc. (TMDX) shares for $4,375,000 on Aug 22, 2024
Date Insider Transaction Shares Price Value Filing
Aug 22, 2024 Waleed H Hassanein S Open-market sale 25,000 held after: 61,643 $175.00 $4,375,000 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Waleed H Hassanein sold 20,000 TransMedics Group, Inc. (TMDX) shares for $3,420,600 on Aug 21, 2024

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Waleed H Hassanein sold 20,000 TransMedics Group, Inc. (TMDX) shares for $3,420,600 on Aug 21, 2024
Date Insider Transaction Shares Price Value Filing
Aug 21, 2024 Waleed H Hassanein S Open-market sale 20,000 held after: 61,643 $171.03 $3,420,600 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 250 rows we hold, 4 are open-market purchases (P) and 159 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for TransMedics Group, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 17, 2026 James R. Tobin G Bona fide gift 18,000 $0.00 $0 SEC filing ↗
Jul 10, 2026 Nicholas Corcoran A Grant or award 11,727 $0.00 $0 SEC filing ↗
Jul 10, 2026 Gerardo Hernandez A Grant or award 17,246 $0.00 $0 SEC filing ↗
Jul 10, 2026 Waleed H Hassanein A Grant or award 49,669 $0.00 $0 SEC filing ↗
Jun 15, 2026 Thomas James Gunderson S Open-market sale 9,624 $75.06 $722.4K SEC filing ↗
Jun 15, 2026 Thomas James Gunderson M Option exercise or conversion 19,285 $2.21 $42.6K SEC filing ↗
May 20, 2026 David Weill A Grant or award 2,922 $0.00 $0 SEC filing ↗
May 20, 2026 Merilee Raines A Grant or award 2,922 $0.00 $0 SEC filing ↗
May 20, 2026 Thomas James Gunderson A Grant or award 2,922 $0.00 $0 SEC filing ↗
May 20, 2026 James R. Tobin A Grant or award 2,922 $0.00 $0 SEC filing ↗
May 20, 2026 Edwin M. Kania Jr. A Grant or award 2,922 $0.00 $0 SEC filing ↗
Mar 4, 2026 Gerardo Hernandez S Open-market sale 5,912 $147.21 $870.3K SEC filing ↗
Mar 4, 2026 Gerardo Hernandez M Option exercise or conversion 5,912 $69.84 $412.9K SEC filing ↗
Mar 4, 2026 Gerardo Hernandez S Open-market sale 1,324 $147.21 $194.9K SEC filing ↗
Mar 4, 2026 Gerardo Hernandez M Option exercise or conversion 1,324 $77.12 $102.1K SEC filing ↗
Mar 4, 2026 David Weill M Option exercise or conversion 3,571 $14.20 $50.7K SEC filing ↗
Mar 4, 2026 David Weill S Open-market sale 3,571 $146.82 $524.3K SEC filing ↗
Mar 2, 2026 Gerardo Hernandez S Open-market sale 375 $139.12 $52.2K SEC filing ↗
Mar 2, 2026 Anil P Ranganath S Open-market sale 864 $139.12 $120.2K SEC filing ↗
Mar 2, 2026 Nicholas Corcoran S Open-market sale 2,966 $139.12 $412.6K SEC filing ↗
Feb 18, 2026 Giovanni Cecere A Grant or award 11,082 $0.00 $0 SEC filing ↗
Jan 23, 2026 Nicholas Corcoran F Shares withheld for taxes 984 $135.30 $133.1K SEC filing ↗
Dec 4, 2025 Gerardo Hernandez S Open-market sale 920 $139.62 $128.5K SEC filing ↗
Dec 3, 2025 David Weill S Open-market sale 5,000 $138.64 $693.2K SEC filing ↗
Dec 3, 2025 David Weill M Option exercise or conversion 5,000 $14.20 $71.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Subsidiaries — 8 legal entities

Subsidiaries of TransMedics Group, Inc.

8 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries TransMedics Group, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Northside Property Group, LLC Montana
Summit Aviation, Inc. Montana
TMDX Realty Holdings LLC Delaware
TransMedics GmbH Germany
TransMedics Pty Ltd. Australia
TransMedics S.r.l. Italy
TransMedics, B.V. The Netherlands
TransMedics, Inc. Delaware
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from TransMedics Group, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from TransMedics Group, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.